October 2018 Review

ICER developed a report on anti-androgen drugs for high risk prostate cancer, including the following therapies: enzalutamide (Xtandi®, Astellas and Medivation), abiraterone acetate (Zytiga®, Janssen), apalutamide (Erleada™, Janssen).

For questions or additional information, please contact info@icer-review.org

Past Reviews

  • September 2009: Active surveillance and Radical prostatectomy
  • December 2008: Brachytherapy and Proton beam therapy
    Proton beam therapy was also the subject of an evidence review by ICER for the Washington State Health Care Authority in May 2014.
  • November 2007: Intensity modulated radiation therapy (IMRT)

View the Key Stakeholders List.


Final Documents

Below you will find the final documents from the assessment review process:

Public CommentsDownload
Report-At-A-GlanceDownload
Final Evidence Report and Meeting SummaryDownload